The hypothesis is that helical tomotherapy could minimize radiation related toxicity by avoiding or limiting doses to structures such as small bowel, external genitalia, skin, bladder, rectum, and femoral neck and head.
This is a phase II study using tomotherapy for radiation treatment delivery along with concurrent 5-FU/mitomycin C for the treatment of T2-T4 cancer of the anal canal. They hypothesis is that helical tomotherapy could minimize radiation related toxicity by avoiding or limiting doses to structures such as small bowel, external genitalia, skin, bladder, rectum, and femoral neck and head. This is expected to limit or reduce treatment related toxicity and hence prevent or reduce treatment breaks. This may result in delivery of radical treatment with better local control and treatment outcome than using the current radiation treatment technique at our center.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
58
30 fractions of tomotherapy treatment
Cross Cancer Institute
Edmonton, Alberta, Canada
Acute Toxicity and Quality of LIfe
Time frame: 3 months
colostomy-free survival and/or overall survival
Time frame: 3 and 5 years
Local Recurrence
Time frame: 3 and 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.